anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses antibodies that bind a protein gp39 (also referred to as CD40 ligand). Preferably, the antibodies are monoclonal antibodies of an IgG1 isotype and bind human gp39. In a preferred embodiment, an antibody of the invention binds an epitope recognized by a monoclonal antibody 24-31, produced by a hybridoma 24-31 (ATTC Accession No.-) or binds an epitope recognized by a monoclonal antibody 89-76, produced by a hybridoma 89-76 (ATCC Accession No.--). Pharmaceutical compositions comprising the antibodies of the invention are also disclosed. The antibodies of the invention are useful for inhibiting B cell proliferation and differentiation, T cell responses and for inducing T cell tolerance. The invention also includes nucleic acid molecules encoding anti-gp39 antibodies, or portions thereof, as well as expression vectors and host cells incorporating the nucleic acid molecules.
Inhalation of room air through an altitude simulator ("Altitrainer"), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.
Oligohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with topiramate use. Decreased sweating and an elevation in body temperature above normal characterized these cases. Some of the cases were reported after exposure to elevated environmental temperatures. 

The majority of the reports have been in pediatric patients. Patients (especially pediatric patients) treated with topiramate should be monitored closely for evidence of decreased sweating and increased body temperature, especially in hot weather. Caution should be used when topiramate is given with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity.
We aimed to investigate the microbial community composition in patients with intracerebral hemorrhage (ICH) and its effect on prognosis. We designed two clinical cohort studies to explore the gut dysbiosis after ICH and their relationship with neurological function prognosis. First, fecal samples from patients with ICH at three time points: T1 (within 24 h of admission), T2 (3 days after surgery), and T3 (7 days after surgery), and healthy volunteers were subjected to 16S rRNA sequencing using Illumina high-throughput sequencing technology. When differential gut microbiota was identified, the correlation between clinical indicators and microbiotas was analyzed. Subsequently, the patients with ICH were categorized into GOOD and POOR groups based on their Glasgow Outcome Scale Extended (GOS-E) score, and the disparities in gut microbiota between the two groups were assessed. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors. The composition and diversity of the gut microbiota in patients with ICH were different from those in the control group and changed dynamically with the extension of the course of cerebral hemorrhage. The abundances of Enterococcaceae, Clostridiales incertae sedis XI, and Peptoniphilaceae were significantly increased in patients with ICH, whereas Bacteroidaceae, Ruminococcaceae, Lachnospiraceae, and Veillonellaceae were significantly reduced. The relative abundance of Enterococcus gradually increased with the extension of the duration of ICH after surgery, and the abundance of Bacteroides gradually decreased. The abundance of Enterococcus before surgery was found to be negatively associated with patient neurological function prognosis. The original ICH score and Lachnospiraceae status were independent risk factors for predicting the prognosis of neurological function in patients with ICH (P < 0.05). Changes in the gut microbiota diversity in patients with ICH were related to prognosis. Lachnospiraceae may have a protective effect on prognosis.IMPORTANCEAcute central nervous system injuries like hemorrhagic stroke are major global health issues. While surgical hematoma removal can alleviate brain damage, severe cases still have a high 1-month mortality rate of up to 40%. Gut microbiota significantly impacts health, and treatments like fecal microbiota transplantation (FMT) and probiotics can improve brain damage by correcting gut microbiota imbalances caused by ischemic stroke. However, few clinical studies have explored this relationship in hemorrhagic stroke. This study investigated the impact of cerebral hemorrhage on the composition of gut microbiota, and we found that Lachnospiraceae were the independent risk factors for poor prognosis in intracerebral hemorrhage (ICH). The findings offer potential insights for the application of FMT in patients with ICH, and it may improve the prognosis of patients.
Cohort 2 participants are in the longitudinal portion of the study and are TGWSM who are planning to initiate feminizing hormone therapy. Individuals in Cohort 2 will participate in study activities for 18 months.
An 83-year-old male with a 55-year history of Crohn's disease, ileocecectomy 40 years prior, and naturopathic treatment for 25 years, presented with nausea, vomiting, and abdominal pain. Computed tomography of abdomen and pelvis demonstrated partial small intestinal obstruction and a 4.4-cm solid left renal mass. After 3 months of recurrent intestinal obstruction and development of a pericolonic abscess, resection of the ileocolonic anastomosis, abscess, and partial nephrectomy were performed. Histopathology demonstrated chronic active enteritis with fistula tract formation, consistent with Crohn's disease, and moderately differentiated small intestinal adenocarcinoma extending from mucosa into subserosa. A submucosal intestinal lymph node-like structure containing adenocarcinoma demonstrated endothelial venules, open marginal and intermediate sinuses, multiple polarized germinal centers, and partial capsule, consistent with an ectopic lymph node, also called a tertiary lymphoid organ. Twenty mesenteric lymph nodes were negative for carcinoma. The renal mass was a papillary renal cell carcinoma, Stage I. Intestinal tertiary lymphoid organs form in chronic immune activation and have variable structures ranging from simple B and T cell clusters to organized groups with high endothelial venules and lymphatic vessels. Encapsulation of tertiary lymphoid organs is rare, with some sources claiming this entity is never encapsulated. To our knowledge, this is the first report of small intestinal adenocarcinoma involving a submucosal encapsulated tertiary lymphoid organ, the prognostic significance of which is uncertain. We suggest increased awareness of intestinal tertiary lymphoid organs as an entity and further studies to delineate the effect their involvement by adenocarcinoma imparts on survival.
PURPOSE: A pharmaceutical composition containing Daphne genkwa extract is provided to activate Nurr1 and to prevent or treat diseases caused by Nurr1 functional disorder. CONSTITUTION: A pharmaceutical composition for preventing or treating diseases caused by Nurr1 functional disorder contains Daphne genkwa extract as an active ingredient. The extract is prepared from stems and roots of Daphne genkwa using organic solvent. A functional food additive with an effect of preventing or treating diseases caused by Nurr1 functional disorder contains the extract as an active ingredient. The composition is administered in the form of liquid, powder, aerosol, capsule, enteric tablet, capsule, or suppository. [Reference numerals] (AA) FOLD VS DMSO; (BB) Daphne genkwa
PURPOSE: A silicon emulsion type aqueous gel cosmetic composition has good feeling in use, effectively controls the removal of sebum and maintains natural and clean make-up for a long time. CONSTITUTION: The cosmetic composition comprises: 1.0 to 15.0 wt.% of porous granular silica, an acrylate/acrylamide copolymer, volatile and non-volatile silicon, a moisturizing agent, and an emulsifier. The volatile silicon includes 1.0 to 15.0 wt.% of cyclomethicone and the non-volatile silicon includes 1.0 to 10.0 wt.% of dimethicone having the viscosity of 5 to 20 cs or methylphenylpolysiloxane having the viscosity of 50 to 100 cs. The mixing ratio of the volatile silicon to the non-volatile silicon is in the range of 60-90:10-40. The emulsifier has the HLB value of 3.0 to 8.0 and includes 0.2 to 3.0 wt.% of at least one selected from the group consisting of silicon glycol copolymer, lauryl methicone polyol, cyclomethicone and dimethicone copolyol. The moisturizing agent includes 1.0 to 15.0 wt.% of a compound selected from the group consisting of 1,3-butyleneglycol, concentrated glycerin, propyleneglycol and betaine.
Rectal cancer accounts for 3.8% of all new cancer diagnosis and for 3.4% of all cancer-related deaths in the world in 2020. Regarding treatment of rectal cancer, it is essential to perform surgery along the anatomical and embryological planes. This technique called total mesorectal excision (TME) reduces the local recurrence rate and improves the survival. Since the early 2000, TME has changed from open to laparoscopic approach due to better results in short-term outcome. Nevertheless, oncological benefits are modest. In 2009 the first ever transanal TME (taTME) war performed. This novel technique combines abdominal with transanal dissection. Because the distal part of the rectum is approached from below, a better visualization of the mesorectal plane resulting in higher rate of free CRM and of complete TME specimen grade (Quirke Score) can be accomplished. However, taTME remains a hot topic in the current scientific literature. In Norway and the Netherlands a higher rate of anastomotic leakage as well as a higher rate of local recurrence (9.5%) with multifocal growth pattern were described.
The invention discloses a composite material of an amorphous hollow ZIF-67 coated silver nanowire, a preparation method and antibacterial application thereof. Belongs to the field of nanometer materials. The composite material takes silver nanowires as a substrate, and a layer of hollow ZIF-67 is uniformly coated outside the silver nanowires, and the composite material has the advantages of regular structure, high yield and excellent antibacterial property. The preparation method of the composite material comprises the following steps: adding cobalt nitrate hexahydrate and dimethyl imidazole into a methanol solution of the silver nanowires under the condition of stirring at normal temperature, and etching the obtained product by using tannic acid to obtain the final composite material. The silver nanowire in the center of the composite material has broad-spectrum antibacterial performance, and the amorphous hollow ZIF-67 in the outer layer of the composite material has high porosity and specific surface area and can be loaded with a large amount of healing promoting drugs. The outer hollow ZIF-67 can be slowly degraded under illumination in the wound microenvironment to release cobalt ions, healing promoting drugs and trace silver ions. In conclusion, the composite material exhibits excellent antibacterial properties and has a prospect in the field of wound repair.
A method to produce polyethylene glycol (PEG) ester comprises the step of reacting PEG with polyhydroxy carboxylic acids or estolides of polyhydroxy fatty acids at a temperature of 120°C to 200°C in the absence of any catalysts. The lack of a catalyst prevents over oxidation and unwanted side-products and the need to remove the catalyst at the end of the process. The PEG preferably has an average molecular weight of 200-2000, more preferably 200-300. The estolide is preferably a diestolide or a triestolide. Preferably, the polyhydroxy carboxylic acid has at least 2 hydroxy groups on adjacent carbon atoms. Preferably, the polyhydroxy carboxylic acid is a fatty acid, more preferably 9,10-dihydroxystearic acid (DHSA). In another aspect, a DHSA PEG ester and its use as a surfactant in a toiletry composition.
The invention relates to a healthy medicated wine. Specifically, the healthy medicated wine is prepared through soaking drugs in 75% alcohol or high-degree white spirit. The healthy medicated wine has the effects of reinforcing the kidneys to strengthen Yang and strengthening the muscles and bones; all the drugs are used in a combined manner, the compatibility is ingenious, the force is specific, and the effect is great. The medicated wine disclosed by the invention has the effects of treating sexual dysfunction, accompanied soreness of the waist and knees, trudge, intolerance to cold and cold limbs, low sexual desire, copious and clear urine or incontinence of urine and the like. The medicated wine can be used for keeping people energetic and prolonging lives of people and is particularly applicable to old and weak people. By using the medicated wine, people can enjoy wine drinking during drinking, and meanwhile, the medicated wine plays roles in keeping in good health, caring health and treating diseases. The medicated wine has important practical significance in the prevention and treatment and health care of human bodies.
The gut microbiota plays a critical role in numerous biochemical processes essential for human health, such as metabolic regulation and immune system modulation. An increasing number of research suggests a strong association between the gut microbiota and carcinogenesis. The diverse metabolites produced by gut microbiota can modulate cellular gene expression, cell cycle dynamics, apoptosis, and immune system functions, thereby exerting a profound influence on cancer development and progression. A healthy gut microbiota promotes substance metabolism, stimulates immune responses, and thereby maintains the long-term homeostasis of the intestinal microenvironment. When the gut microbiota becomes imbalanced and disrupts the homeostasis of the intestinal microenvironment, the risk of various diseases increases. This review aims to elucidate the impact of gut microbial metabolites on cancer initiation and progression, focusing on short-chain fatty acids (SCFAs), polyamines (PAs), hydrogen sulfide (H2S), secondary bile acids (SBAs), and microbial tryptophan catabolites (MTCs). By detailing the roles and molecular mechanisms of these metabolites in cancer pathogenesis and therapy, this article sheds light on dual effects on the host at different concentrations of metabolites and offers new insights into cancer research.
BACKGROUND: SARS-CoV-2 vaccines are safe and effective against infection and severe COVID-19 disease worldwide. Certain co-morbid conditions cause immune dysfunction and may reduce immune response to vaccination. In contrast, those with co-morbidities may practice infection prevention strategies. Thus, the real-world clinical impact of co-morbidities on SARS-CoV-2 infection in the recent post-vaccination period is not well established. This study was performed to understand the epidemiology of Omicron breakthrough infection and evaluate associations with number of comorbidities in a vaccinated and boosted population.
METHODS AND FINDINGS: A retrospective clinical cohort study was performed utilizing the Northwestern Medicine Enterprise Data Warehouse. Our study population was identified as fully vaccinated adults with at least one booster. The primary risk factor of interest was the number of co-morbidities. The primary outcome was the incidence and time to the first positive SARS-CoV-2 molecular test in the Omicron predominant era. Multivariable Cox modeling analyses to determine the hazard of SARS-CoV-2 infection were stratified by calendar time (Period 1: January 1 -June 30, 2022; Period 2: July 1 -December 31, 2022) due to violations in the proportional hazards assumption. In total, 133,191 patients were analyzed. During Period 1, having 3+ comorbidities was associated with increased hazard for breakthrough (HR = 1.16 CI 1.08-1.26). During Period 2 of the study, having 2 comorbidities (HR = 1.45 95% CI 1.26-1.67) and having 3+ comorbidities (HR 1.73, 95% CI 1.51-1.97) were associated with increased hazard for Omicron breakthrough. Older age was associated with decreased hazard in Period 1 of follow-up. Interaction terms for calendar time indicated significant changes in hazard for many factors between the first and second halves of the follow-up period.
CONCLUSIONS: Omicron breakthrough is common with significantly higher risk for our most vulnerable patients with multiple co-morbidities. Age plays an important role in breakthrough infection with the highest incidence among young adults, which may be due to age-related behavioral factors. These findings reflect real-world differences in immunity and exposure risk behaviors for populations vulnerable to COVID-19.
Patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
AIM: To explore the usefulness of a co-designed wordless book showing processes of receiving COVID-19 vaccines designed by, and for, adults with intellectual disabilities.
METHODS: A qualitative evaluation of the resource using mixed methods. Semi-structured interviews were conducted with people with intellectual disabilities, carers and health professionals about resource content, and use. This was analysed thematically. A survey was circulated to intellectual disabilities networks to understand resource need, use, sharing and content.
RESULTS: Understanding the COVID-19 vaccine was a process, not a single event using one resource. A visual resource had a place in facilitating conversations about vaccines between people with intellectual disabilities and carers. Differing perspectives were expressed regarding personal needs, existing awareness of vaccine programmes and communication preferences. Changes were suggested to improve the suggested storyline and relevance around COVID-19 restrictions changing.
CONCLUSION: A visual resource may help conversations about the COVID-19 vaccine for people with intellectual disabilities.
New antibiotic kedarcidin (I) is characterised by its physico-chemical properties. It comprises a non-protein chromophore and a single-chain polypeptide, of which 3 variants are present. The main variant has defined 114 aminoacid sequence; one minor variant lacks the N-terminal Ala; the other minor variant lacks the N-terminal Ala-Ser. Pref. (I) is produced by culturing the new Streptoalloteichus strain L585-6 (ATCC 53650) in a medium contg. assimilable C and N sources under submerged aerobic conditions.
The utility model provides a snore stop patch which is composed of an anti-adhesive paper, a drug leaching double-sided gummed paper, an elastic snore stop plastic film and a drug leaching decorative paper. The elastic snore stop plastic film is fixedly pasted between the drug leaching decorative paper and the back face of the drug leaching double-sided gummed paper. And the anti-adhesive paper with tearing seam in the middle is pasted to connect on the front surface of the drug leaching double-sided gummed paper. The snore stop patch is attached on the nose bridge when in use. The snore stop patch can effectively make two sides of nasal ala expand, improve the respiratory intensity of nose, and reduce the snore voice, therefore having distinct treatment effect to rhinitis patients, obesity individuals, pregnant women, athletes, children, etc., and improving sleeping quality. Compared with prior technology, the snore stop patch of the utility model has the advantages of reasonable design, simple structure, easy process, small volume, convenient use, good effect of snore stop, fine air permeability, therefore having good application and use value.
The incubator temperature was adjusted between 28-30 C, and it was administered while the baby was awake and one hour after feeding. Before the massage, the hands were washed and warmed. Just before each phototherapy application, 10-minute baby massage was performed by the researcher.Then phototherapy was applied.
Teratogenic plants can be found in pastures in different parts of the world and represent a threat to the reproduction of ruminants. In the northeast region of Brazil, several studies have indicated that Cenostigma pyramidale (Tul.) Gagnon & G.P.Lewis is one of the main poisonous plants that causes reproductive problems in sheep and goats. In this context, the present study reviewed spontaneous and experimental poisonings reports by C. pyramidale in sheep and goats, as well as analyzing the phytochemical evidence related to this species. The scientific documents were retrieved from different databases and, after applying the selection criteria, a total of 16 articles published between 2000 and 2024 were included in this review. Cenostigma pyramidale causes embryonic loss, abortion, and congenital malformations in pregnant sheep and goats in the Brazilian semi-arid region. The main malformations observed in newborn animals are arthrogryposis, scoliosis, micrognathia, multiple skull deformities, cleft palate, and brachygnathism. Many secondary metabolites have already been isolated from C. pyramidale, however, to date, no evidence has been found regarding the possible teratogenic compounds that occur in this plant. From this perspective, new phytochemical studies are necessary to help unravel the mechanisms of action of embryotoxic agents from C. pyramidale.
The present invention relates to a composition for preventing and treating cancer including a Cyclin-dependent kinase 9 CDK9 inhibitor as an active ingredient. Pharmacopoeial models from 1,260,775 virtual chemical libraries are used to obtain the first 1,820 pharmacopoeial virtual hits by executing a virtual search operation using a computer. A program called CDOCKER, which is a molecular dynamics (MD) simulated-annealing-based algorithm, is used to obtain 500 second virtual hits with the consensus scores of 5 or higher. The second virtual hits are used as a target to derive 15 third virtual hits by using a visual inspection operation. In-vitro activities of the derived compounds related to the CDK9 are measured to find four chemical compounds as anti-cancer substance candidates. The chemical compounds can be utilized for cancer treatment and as anti-cancer drugs.
OBJECTIVE: To determine whether residing in a hospital bed that previously held an occupant with Clostridioides difficile increases the risk of hospital-onset C. difficile infection (HO-CDI).
METHODS: In this retrospective cohort study, we used a real-time location system to track the movement of hospital beds in 2 academic hospitals from April 2018 to August 2019. We abstracted patient demographics, clinical characteristics, and C. difficile polymerase chain reaction (PCR) results from the medical record. We defined patients as being exposed to a potentially "contaminated" bed or room if, within the preceding 7 days from their HO-CDI diagnosis, they resided in a bed or room respectively, that held an occupant with C. difficile in the previous 90 days. We used multivariable logistic regression to determine whether residing in a contaminated bed was associated with HO-CDI after controlling for time at risk and requiring intensive care. We assessed mediation and interaction from a contaminated hospital room.
RESULTS: Of 25,032 hospital encounters with 18,860 unique patients, we identified 237 cases of HO-CDI. Exposure to a contaminated bed was associated with HO-CDI in unadjusted analyses (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.4-2.31) and adjusted analyses (OR, 1.5; 95% CI, 1.2-2.0). Most of this effect was due to both mediation from and interaction with a contaminated hospital room.
CONCLUSIONS: Residing in a hospital bed or room that previously had a patient with C. difficile increases the risk of HO-CDI. Increased attention to cleaning and disinfecting the healthcare environment may reduce hospital transmission of C. difficile.